These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7064590)

  • 21. Hemodialysis-induced hypoglycemia in diabetic patients.
    Jackson MA; Holland MR; Nicholas J; Lodwick R; Forster D; Macdonald IA
    Clin Nephrol; 2000 Jul; 54(1):30-4. PubMed ID: 10939754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
    Don BR; Spin G; Nestorov I; Hutmacher M; Rose A; Kaysen GA
    J Pharm Pharmacol; 2005 Nov; 57(11):1407-13. PubMed ID: 16259772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic haemodialysis patients.
    Heguilén RM; Sciurano C; Bellusci AD; Fried P; Mittelman G; Rosa Diez G; Bernasconi AR
    Nephrol Dial Transplant; 2005 Mar; 20(3):591-7. PubMed ID: 15687112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcium in patients on hemodialysis.
    Ring T; Halkier P; Hansen HH; Sanden AK; Nielsen C
    Clin Nephrol; 1995 May; 43(5):332-4. PubMed ID: 7634549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Calcium balance during hemodialysis under conditions of different calcium concentrations of the dialysate].
    Buchali K; Precht K; Raabe H; Neymeyer HG; Sieberth R
    Z Urol Nephrol; 1974 Nov; 67(11):819-22. PubMed ID: 4460594
    [No Abstract]   [Full Text] [Related]  

  • 27. Calcium metabolism in patients treated with maintenance haemodialysis.
    Massry SG; Kleeman CR
    Triangle; 1971; 10(4):147-56. PubMed ID: 5148931
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
    Eriksson T; Höglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA
    J Pharm Pharmacol; 2003 Dec; 55(12):1701-6. PubMed ID: 14738599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Occult hypoglycemia caused by hemodialysis.
    Jackson MA; Holland MR; Nicholas J; Talbot M; Spencer H; Lodwick R; Fuhrmann C; Forster D; Macdonald IA
    Clin Nephrol; 1999 Apr; 51(4):242-7. PubMed ID: 10230557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The use of xidifon for the correction of phosphorus-calcium metabolism in patients in the terminal stage of chronic kidney failure who are on programmed hemodialysis].
    Konstantinova OV; Ianenko EK; Danilkov AP; Pashkin IN
    Urol Nefrol (Mosk); 1997; (3):23-5. PubMed ID: 9245050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation.
    Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Manini P; Andreoli R; Cabassi A
    Nephrol Dial Transplant; 2006 May; 21(5):1402-6. PubMed ID: 16504979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ciprofloxacin and oxociprofloxacin pharmacokinetics in patients on haemodialysis.
    Drinovec J; Mrhar A; Bren A; Primozic S; Karba R; Varl J; Kozjek F
    J Chemother; 1989 Jul; 1(4 Suppl):565-6. PubMed ID: 16312534
    [No Abstract]   [Full Text] [Related]  

  • 33. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
    Sigrist MK; Devlin L; Taal MW; Fluck RJ; McIntyre CW
    Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study of calcium metabolism by Ca47 during chronic renal insufficiency].
    Chechan C; Lelievre G; Lefebvre J; Marchandise X; Duchatelle P; Moukarzel-Catteau C; Tacquet A
    Lille Med; 1975 Nov; 20(9):783-7. PubMed ID: 1207363
    [No Abstract]   [Full Text] [Related]  

  • 35. Neutron activation analysis of a hand-a method of monitoring progressive bone disease.
    McIntosh JA; Catto GR
    Biomed Eng; 1974 Jun; 9(6):254-6 passim. PubMed ID: 4837582
    [No Abstract]   [Full Text] [Related]  

  • 36. [Critical evaluation of some laboratory parameters of derangements in calcium, magnesium and phosphorus metabolism in patients treated by chronic intermittent haemodialysis (author's transl)].
    Revúsová V; Zvara V; Gratzlová J; Reznícek J; Borosová E
    Bratisl Lek Listy; 1976 Apr; 65(4):378-83. PubMed ID: 963558
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pharmacokinetics of ofloxacin in patients with severe renal impairment].
    Bandai H; Tsubakihara Y; Yamato E; Yokoyama K; Okada N; Nakanishi I; Iida N
    Nihon Jinzo Gakkai Shi; 1987 Nov; 29(11):1429-33. PubMed ID: 3482706
    [No Abstract]   [Full Text] [Related]  

  • 38. Changes in total and ultrafilterable plasma calcium and magnesium during hemodialysis.
    Ogden DA; Holmes JH
    Trans Am Soc Artif Intern Organs; 1966; 12():200-4. PubMed ID: 5960703
    [No Abstract]   [Full Text] [Related]  

  • 39. Proceedings: On plasma Ca concentration in patients under chronic hemodialysis. Clinical observations and considerations from absorption and excretion tests of 47Ca.
    Suzuki M; Gejyo F; Hirasawa Y
    Calcif Tissue Res; 1974; 15(2):159. PubMed ID: 4844398
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of hemodialysis on serum concentration of isepamicin in a patient with endstage renal failure.
    Kuranari M; Nawata T; Sato Y; Sakata T; Kodama Y; Takeyama M
    Ann Pharmacother; 1993 Oct; 27(10):1284-5. PubMed ID: 8251702
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.